Clinical trial
Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE)
NCT00472901 · Clinuvel Pharmaceuticals Limited, Industry · Completed
Key facts
| NCT number | NCT00472901 |
|---|---|
| Title | Phase III Trial of CUV1647 in Polymorphic Light Eruption (PLE) |
| Official title | A Phase III, Randomised, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of CUV1647 in Patients Suffering From Polymorphic Light Eruption (PLE). |
| Lead sponsor | Clinuvel Pharmaceuticals Limited, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Polymorphic Light Eruption (PLE) |
| Intervention type | Drug |
| Interventions | Afamelanotide (CUV1647) |
| Enrollment | 18 |
| Start date | May 1, 2007 |
| Primary completion | Dec 1, 2009 |
| Completion | Sep 1, 2010 |
| First posted | May 14, 2007 |
| Last update posted | Oct 5, 2011 |
| Countries | Australia, Austria, United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: